MedTrace Logo

Study of a Potential Preventive Vaccine Against HIV in Healthy Volunteers

NCT00545987 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-05-05

No results posted yet for this study

Summary

This study will test the safety of a HIV DNA vaccine after it is injected into your muscle using an electroporation device (TriGrid™ Delivery System made by Ichor Medical Systems), and will test the ability of the vaccine to help your body make antibodies and T-Cells.

In this study, we would like to learn about the effects that electroporation of the HIV DNA has on you and your immune system.

Conditions

  • HIV Infections

Interventions

DEVICE

TriGrid™ Delivery System

Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.

DEVICE

conventional intramuscular injection

administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection

Sponsors & Collaborators

  • Aaron Diamond AIDS Research Center

    collaborator OTHER

  • Bill and Melinda Gates Foundation

    collaborator OTHER

  • Ichor Medical Systems Incorporated

    collaborator INDUSTRY

  • International AIDS Vaccine Initiative

    collaborator NETWORK

  • Rockefeller University

    lead OTHER

Principal Investigators

  • David Ho, M.D. · The Aaron Diamond AIDS Research Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-10-31
Completion
2011-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00545987 on ClinicalTrials.gov